peptides
Retatrutide 10mg
Retatrutide is a next-generation triple-receptor agonist studied for its profound effects on glucose regulation, energy expenditure, and fat oxidation. Research models show some of the most significant weight reductions of any peptide class.
Research-observed benefits
- ›Appetite suppression
- ›Accelerated fat loss
- ›Improved insulin sensitivity
- ›Metabolic rate uplift
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
200 units
Order type
Purchase option
Quantity
Total
$50
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
Retatrutide — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Triple agonist of GLP-1, GIP, and glucagon receptors. Simultaneously slows gastric emptying (GLP-1), enhances insulin secretion (GIP), and increases basal energy expenditure (glucagon).
How It Helps
Research models show the most aggressive appetite suppression and fat oxidation of any incretin-class peptide to date, with meaningful improvements in insulin sensitivity and lipid panels.
Half-Life
~6 days (supports once-weekly dosing)
Onset of Effects
Appetite changes within 3–7 days; weight effects compounding through weeks 4–24.
Administration
Subcutaneous injection — abdomen, thigh, or upper buttock. 27–31G insulin syringe.
Storage
Lyophilized: store at –20°C, stable 24+ months. Reconstituted: refrigerate 2–8°C, use within 28 days.
Reconstitution Guide
Add 2 mL bacteriostatic water to a 10 mg vial → 5 mg/mL (5 mg per 1 mL). 1 mL BAC → 10 mg/mL for compact dosing. Swirl gently, do not shake.
Precise Dosing Protocols
Weight-loss research titration
- Dose:
- Start 2 mg/week → step up 2 mg every 4 weeks toward 8–12 mg
- Frequency:
- Once weekly SC
- Duration:
- 24–48 weeks
- Notes:
- Phase-2 protocol pattern
Maintenance research
- Dose:
- 4–8 mg weekly
- Frequency:
- Once weekly SC
- Duration:
- Ongoing in study window
Stacks Well With
- ›MOTS-c (mitochondrial fat oxidation)
- ›Tesamorelin (lean mass retention)
- ›NAD+ (energy during caloric drop)
Research-Observed Side Effects
- •Nausea (titration period)
- •Transient appetite loss
- •GI changes — constipation or loose stool
- •Mild fatigue early
Translational Cautions
- •Personal/family history of MTC or MEN2 in human translation
- •Active pancreatitis flagged in literature
Cycling Guidance
Most research protocols run 24-week titration arcs followed by 4–8 week observation/washout periods.
Research Highlights
- ▸NEJM 2023 (Jastreboff et al.): up to 24.2% body weight reduction at 48 weeks, 12 mg dose.
- ▸Significant reductions in HbA1c and triglycerides across all dose arms.
- ▸Glucagon-arm activity increases resting energy expenditure — unique vs. dual or single agonists.